Shuimu Biosciences

This installment of Supplier Spotlight® highlights Shuimu Biosciences, a definitive force at the dynamic intersection of artificial intelligence and structural biology. They provide a complete, integrated suite of solutions, beginning with featuring the world’s largest commercial platform that delivers stunning atomic-level resolution. Their services are available on Scientist.com.

What is your company’s mission?

Founded in 2017 at Tsinghua University, ShuimuBio aims to provide advanced and reliable structural biology solutions by leveraging cutting-edge cryo-electron microscopy (cryo-EM) and protein science technologies. As the world’s largest commercial cryo-EM platform, the company is committed to realizing a one-stop-solution from gene sequence to high-precision 3D protein structure, relying on Tsinghua University’s profound scientific research and technical accumulation in structural biology. By overcoming technical bottlenecks in structural analysis and protein preparation through standardized and automated engineering methods, ShuimuBio supports life science research and drug development, including vaccines, antibody drugs and small-molecule drugs, delivering critical structural insights to accelerate scientific innovation and clinical translation.

What products and services do you offer?

We provide a complete, integrated suite of solutions, beginning with the world’s largest commercial platform that delivers stunning atomic-level resolution. Shuimu developed TOTEM™ cryo-EM with 1.4Å (angstrom) resolution and SMART™ cloud infrastructure, which is the first end-to-end AI workflow that slashes data processing time from months to hours while enabling real-time global collaboration. This powerful synergy between cutting-edge hardware and intelligent software is further enhanced by our GraFuture™ support films, which ensure sample integrity for top-tier institutions worldwide. As a recognized National High-Tech Enterprise, we are proud to serve over 1,400 leading research labs, bridging the power of AI and cryo-EM to unlock life’s deepest mysteries and fuel the next wave of scientific and pharmaceutical breakthroughs.

What problems do you solve?

• Structural Analysis Bottlenecks: Overcomes challenges such as small protein molecular weight, low concentration, strong background noise, air-liquid interface damage and preferred orientation (via GraFuture™ grids and AI algorithms).
• Difficult-to-crystallize Samples: Enables high-resolution structure analysis for flexible complexes, membrane proteins and viral particles (vs. traditional X-ray crystallography’s reliance on crystals).
• Drug R&D Efficiency: Accelerates vaccine development (viral structure analysis, quality control, antibody-vaccine interaction), antibody drug design (epitope mapping, mechanism study) and small-molecule drug discovery (target structure, binding mechanism, fragment-based screening).
• Protein Preparation Challenges: Resolves issues with hard-to-express proteins, maintains native protein conformation (reduces transport impact via in-house expression/purification) and ensures sample quality (strict QC via SDS-PAGE, HPLC, etc.).
• Long R&D Cycles: Shortens structural analysis time to 7 – 14 days with automated data collection and AI-driven data processing.

What are the most innovative tools and technologies that you offer?

Unlock the full potential of cryo-electron microscopy (cryo-EM) with Shuimu Biosciences’ cutting-edge solutions. Our SMART Suite revolutionizes SPA (Single Particle Analysis) workflows by synergizing AI-driven software, advanced materials and high-performance computing, delivering unprecedented speed and precision. For complex cryo-ET (tomography) projects, our modular SMART integration streamlines 3D structural imaging of cellular organelles, viral particles and large protein assemblies in their native context.

All workflows are powered by our secure SMART Cloud Platform, enabling seamless remote data access, collaboration and storage — all backed by a fleet of 8 top-tier 300 kV cryo-EMs (including domestically developed models rivaling global benchmarks). Our GraFuture™ graphene grids eliminate background noise and enhance signal sensitivity, even for ultra-low-concentration samples, while our automated high-throughput pipeline operates at >97% reliability, 24/7. From gene cloning to data delivery, our end-to-end workflow minimizes delays and sample loss, accelerating your path to discovery. Trust Shuimu Biosciences to elevate your structural biology research to new heights.

What are your competitive advantages?

• Global-scale Cryo-EM Platform: The largest commercial cryo-EM platform in Asia (8×300 kV cryo-EMs) with >330 annual operational days per instrument.
• Proven Expertise: >2,000 cryo-EM project experiences, >1,200 resolved protein structures (best resolution 1.4 Å) and 80%+ success rate for MicroED projects.
• Top-tier Scientific Team: PhD-level scientists specializing in structural biology, protein science and computational biology.
• Speed & Efficiency: 24h response to time-sharing bookings, 7 – 14 days for cryo-EM structure analysis and 1-month turnaround for crystal structure services.
• In-house Innovations: Proprietary AI algorithms, graphene grids and eTasED software (enhances resolution and data efficiency).
• Strict Quality Control: Ensures sample purity (>90% for proteins, >95% for crystals) and reliable data via regular equipment maintenance and multi-dimensional characterization.
• Flexible Collaboration: Customizable production scales, competitive pricing and remote monitoring/tools for real-time project tracking.

Who are your clients?

ShuimuBio serves over 500 clients worldwide, spanning leading academic institutions and biopharmaceutical enterprises. Its academic clients cover basic research in structural biology, virology and biochemistry. Industrial clients include multinational pharmaceutical companies and leading biotech firms, focusing on vaccine development, antibody drug design, small-molecule drug discovery and quality control. These clients span diverse fields such as life science research, infectious disease prevention, oncology and neurological disorders, relying on ShuimuBio’s solutions to accelerate R&D and clinical translation.

What new products and services are you developing in 2026?

In 2026, Shuimu Biosciences will roll out a suite of new products and services centered on life science technologies and product ecosystems. First, in terms of protein products, the company will develop and market off-the-shelf proteins targeting popular biological targets; meanwhile, it will launch new tool proteins — these can not only support structural analysis but also replace commercial reagents to achieve cost reduction and efficiency improvement. Additionally, for technology platform services, Shuimu Biosciences will complete the construction of the Cryo-ET platform and fulfill its first commercial order, officially launching this new technical service to the market. It will also upgrade the Cryo-EM SMART Integrated Computing Platform from data collection and 3D reconstruction to model building, while deepening collaborations with universities and industry partners to advance the platform’s ecological development. Furthermore, regarding data system services, the company will partner with industrial and scientific research institutions to build a high-quality structural biology data system and establish an intelligent data infrastructure for the life science field — this initiative will accelerate the deep integration of artificial intelligence and life sciences.

Where are your laboratories and offices located?

ShuimuBio’s headquarters and main office are situated on the 4th Floor, Building 2, Bio-Tech Center, Life Science Park, Changping District, Beijing. The company operates state-of-the-art cryo-EM laboratories in two strategic locations: Beijing hosts 2 of its 300 kV cryo-EMs, while Hangzhou houses 6 additional 300 kV cryo-Ems.

Connect with Shuimu Biosciences on shuimubio.com and Scientist.com.